Crescent Biopharma, Inc.
CBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $10 | $75 | $1,160 |
| % Growth | -100% | -86.7% | -93.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $10 | $75 | $1,160 |
| % Margin | – | 100% | 100% | 100% |
| R&D Expenses | $56,136 | $20,072 | $28,391 | $47,492 |
| G&A Expenses | $12,628 | $19,213 | $19,087 | $17,115 |
| SG&A Expenses | $12,628 | $19,213 | $19,087 | $17,115 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $1 | $0 | $0 |
| Operating Expenses | $68,764 | $39,285 | $47,478 | $64,607 |
| Operating Income | -$68,764 | -$39,275 | -$47,403 | -$63,447 |
| % Margin | – | -392,752.9% | -63,204.4% | -5,470.7% |
| Other Income/Exp. Net | -$2,704 | $2,377 | $715 | $20 |
| Pre-Tax Income | -$71,468 | -$36,899 | -$46,688 | -$63,427 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$71,468 | -$36,899 | -$46,689 | -$63,427 |
| % Margin | – | -368,994.2% | -62,251.7% | -5,469% |
| EPS | -0.59 | -0.58 | -0.89 | -1.23 |
| % Growth | -1.7% | 34.8% | 27.6% | – |
| EPS Diluted | -0.59 | -0.58 | -0.89 | -1.23 |
| Weighted Avg Shares Out | 64,477 | 63,342 | 52,531 | 51,453 |
| Weighted Avg Shares Out Dil | 64,477 | 63,342 | 52,531 | 51,453 |
| Supplemental Information | – | – | – | – |
| Interest Income | $935 | $2,376 | $715 | $20 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $68,764 | $153 | $207 | $265 |
| EBITDA | $0 | -$39,121 | -$47,196 | -$63,183 |
| % Margin | – | -391,213.6% | -62,927.6% | -5,447.9% |